ArticleEndocrine2025
Effect of diabetic kidney disease on sarcopenia and quality of life in patients with type 1 diabetes.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research trends and potential molecular intersections between diabetic kidney disease and sarcopenia: a 21-year bibliometric and bioinformatics analysis.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSarcopenia can develop at a younger age as a complication in patients with type 1 diabetes (T1D). This study aimed to evaluate the association of sarcopenia with diabetic kidney disease (DKD) in non-elderly patients with T1D.
methodsThis cross-sectional study enrolled 100 patients with T1D, including 50 individuals with DKD and 50 without. Median age of patients was 31 years (25-75th percentile: 24.2-44) and a median duration of T1D was 10.1 years (25-75th percentile: 9-13). Hand grip strength (HGS), skeletal muscle mass index (SMMI) were utilized to assess the presence of sarcopenia. The Sarcopenia Quality of Life (SarQoL) and Pittsburgh Sleep Quality questionnaires were used to evaluate the quality of life.
resultsSarcopenia was diagnosed in 19 out of 100 patients (19%). The prevalence of sarcopenia was 36% (18 out of 50) in the DKD group and 2% (1 out of 50) in the non-DKD group. Sarcopenia was more prevalent in the DKD group (p < 0.001). Urinary albumin-to-creatinine ratio (UACR) levels were a significant predictor of sarcopenia (odds ratio 1.031, 95% CI 1.009-1.058; p = 0.005). The median HGS and SMMI values were lower in the sarcopenia group than in the non-DKD group (p = 0.006 and p = 0.001 respectively). Furthermore, the SarQol scores and sleep quality were lower in the sarcopenia group compered to the non-DKD group (p = 0.018 and p < 0.05, respectively).
conclusionsSarcopenia may occur earlier in non-elderly patients with T1D and DKD, adversely affecting the quality of life. Early screening for sarcopenia should be considered in individuals with DKD.
Indexed as
Identifiers
40835810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.